Gene Therapy of Canavan Disease: AAV-2 Vector for Neurosurgical Delivery of Aspartoacylase Gene ( ASPA ) to the Human Brain
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
This clinical protocol describes virus-based gene transfer for Canavan disease, a childhood leukodystrophy. Canavan disease, also known as Van Bogaert-Bertrand disease, is a monogeneic, autosomal recessive disease in which the gene coding for the enzyme aspartoacylase (ASPA) is defective. The lack of functional enzyme leads to an increase in the central nervous system of the substrate molecule, N-acetyl-aspartate (NAA), which impairs normal myelination and results in spongiform degeneration of the brain. No effective treatment currently exists; however, virus-based gene transfer has the potential to arrest or reverse the course of this otherwise fatal condition. This procedure involves neurosurgical administration of approximately 900 billion genomic particles (approximately 10 billion infectious particles) of recombinant adeno-associated virus (AAV) containing the aspartoacylase gene (ASPA) directly to affected regions of the brain in each of 21 patients with Canavan disease. Pre- and post-delivery assessments include a battery of noninvasive biochemical, radiological, and neurological tests. This gene transfer study represents the first clinical use of AAV in the human brain and the first instance of viral gene transfer for a neurodegenerative disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“AAV vector administration to the CNS has an excellent safety and efficacy profile.”
From AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease (2018) · cites this paper as [57]
In the citing paper
“Global CNS concentrations of NAA, as measured by magnetic resonance (MR) spectroscopy, were decreased after AAV2-ASPA delivery, especially in the basal ganglia.”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [56]
In the citing paper
“Finally, improvement in these biochemical and imaging biomarkers was accompanied by stabilization to improvements in gross motor functioning, although social and cognitive recovery was less consistent.”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [56]
In the citing paper
“Similarly, the T1 relaxation time decreased in white-matter tracts, especially the splenium of the corpus callosum, and some patients demonstrated a halting or reversal of brain atrophy.”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [56]
In the citing paper
“The procedure was well tolerated with only minimal systemic inflammation and a demonstrated, promising long-term safety and clinical efficacy.”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [56]
Citations
Cites
Safety and Efficacy of Recombinant Human α-Galactosidase A Replacement Therapy in Fabry's Disease
Eng, C. M., Guffon, N., Wilcox, W. R., Germain, D. P., Lee, P., Waldek, S., Caplan, L., Linthorst, G. E., & Desnick, R. J. (2001) · New England Journal of Medicine · doi:10.1056/nejm200107053450102 · Cited by 1,559
Xiao, X., Li, J., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.3.2224-2232.1998 · Cited by 1,381 · cited 1×
“We use a modified version of previously described protocols for generating clinical grade rAAV vectors (Ferrari et al ., 1997; Xiao et al ., 1998).”
Enzyme Replacement Therapy in Fabry Disease: A Randomized Controlled Trial
Schiffmann, R., Kopp, J. B., Austin III, H. A., Sabnis, S., Moore, D. F., Weibel, T., Balow, J. E., & Brady, R. O. (2001) · JAMA · doi:10.1001/jama.285.21.2743 · Cited by 1,302
Kaplitt, M. G., Leone, P., Samulski, R. J., Xiao, X., Pfaff, D. W., O'Malley, K. L., & During, M. J. (1994) · Nature Genetics · doi:10.1038/ng1094-148 · Cited by 1,031
Self-citationKay, M. A., Manno, C. S., Ragni, M. V., Larson, P. J., Couto, L. B., McClelland, A., Glader, B., Chew, A. J., J Tai, S., Herzog, R. W., et al. (2000) · Nature Genetics · doi:10.1038/73464 · Cited by 1,022
Normal maturation of the neonatal and infant brain: MR imaging at 1.5 T.
Barkovich, A. J., Kjos, B. O., Jackson, D. E., & Norman, D. (1988) · Radiology · doi:10.1148/radiology.166.1.3336675 · Cited by 744 · cited 1×
“Conventional T1-weighted and T2-weighted images have been used by many groups to study the development of the brain during infancy (Barkovich, 1988).”
Kreis, R., Ernst, T., & Ross, B. D. (1993) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910300405 · Cited by 681 · cited 1×
“1 H MRS provides a method of performing quantitative and semi-quantitative measurements of the brain (Kreis et al ., 1993).”
Michaelis, T., Merboldt, K. D., Bruhn, H., Hänicke, W., & Frahm, J. (1993) · Radiology · doi:10.1148/radiology.187.1.8451417 · Cited by 556
SAFETY AND EFFICACY OF RECOMBINANT HUMAN a -GALACTOSIDASE A REPLACEMENT THERAPY IN FABRY'S DISEASE
Ng, M., Uffon, N. A. G., Ilcox, W. I. R. W., Ermain, P. G., Ee, P., Aldek, S. T. W., Aplan, L. O. C., Inthorst, E. L., & Esnick, R. O. J. D. (2001) · Cited by 482
Bankiewicz, K. S., Eberling, J. L., Kohutnicka, M., Jagust, W., Pivirotto, P., Bringas, J., Cunningham, J., Budinger, T. F., & Harvey-White, J. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7408 · Cited by 406
Research works printed but not linked: 6
- LEONE P., 1999, Curr. Opin. Mol. Ther., 1, 487
- 10.1002/ana.102 · doi:10.1002/ana.102
- 10.1002/(SICI)1521-2254(200005/06)2:3<165::AID-JGM107>3.3.CO;2-I · doi:10.1002/(sici)1521-2254(200005/06)2:3<165::aid-jgm107>3.3.co;2-i
- STEEN R.G., 1997, Am. J. Neuroradiol., 18, 819
- WANG Z.J., 1998, Neuroimaging Clin. N. Am., 8, 781
- ZELNIK N., 1994, Dev. Med. Child. Neurol., 36, 845
Cited by
N-Acetylaspartate in the CNS: From neurodiagnostics to neurobiology
Moffett, J. R., Ross, B., Arun, P., Madhavarao, C. N., & Namboodiri, A. M. A. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2006.12.003 · Cited by 1,405
Therapeutic in vivo gene transfer for genetic disease using AAV: Progress and challenges
Mingozzi, F., & High, K. A. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2988 · Cited by 893
Current clinical applications of in vivo gene therapy with AAVs
Mendell, J. R., Al-Zaidy, S. A., Rodino-Klapac, L. R., Goodspeed, K., Gray, S. J., Kay, C. N., Boye, S. L., Boye, S. E., George, L. A., Salabarria, S., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.007 · Cited by 743
“Whereas this approach was well tolerated and led to both biochemical and clinical improvements, improved viral-mediated gene-transfer technologies using AAV2 were studied in a phase 1 study of intracranial infusions via six cranial burr holes in patients with CD (n = 13).(56) The procedure was well tolerated with only…”
BackgroundWorgall, S., Sondhi, D., Hackett, N. R., Kosofsky, B., Kekatpure, M. V., Neyzi, N., Dyke, J. P., Ballon, D., Heier, L., Greenwald, B. M., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.022 · Cited by 402
Stable antibody expression at therapeutic levels using the 2A peptide
Fang, J., Qian, J.-J., Yi, S., Harding, T. C., Tu, G. H., VanRoey, M., & Jooss, K. (2005) · Nature Biotechnology · doi:10.1038/nbt1087 · Cited by 370
Metadata
- Authors
- Janson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D.-J., Shera, D., Hurh, P., Rupin, J., Saslow, E., Goldfarb, O., Goldberg, M., Larijani, G., Sharrar, W., Liouterman, L., Camp, A., Kolodny, E., Samulski, J., & Leone, P.
- Affiliations
- Robert Wood Johnson Medical School-UMDNJ and Cooper Hospital
- University of North Carolina at Chapel Hill (US)
- Children's Hospital of Philadelphia (US)
- Venue
- Human Gene Therapy
- Publisher
- SAGE Publications
- Published
- 2002-07-20
- Volume
- 13
- Issue
- 11
- Pages
- 1391-1412
- ISSN
- 1043-0342 (ISSN-L)
- 1557-7422
- OpenAlex
- W2153042097
- Cited by
- 255
- References
- 54
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 15 · 2023: 11 · 2022: 3 · 2021: 7 · 2020: 10 · 2019: 6 · 2018: 7 · 2017: 6 · 2016: 13 · 2015: 7 · 2014: 11 · 2013: 12 · 2012: 13
- FWCI
- 9.82
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)
- Locations
- Human Gene Therapy (publishedVersion)
- PubMed (publishedVersion)
- DigitalGeorgetown (Georgetown University Library) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- Canavan disease, aspartoacylase, gene therapy, leukodystrophy, N-acetylaspartate, myelination, neurodegenerative diseases, recombinant adeno-associated virus, substrate accumulation
- MeSH terms
- Dependovirus, Amidohydrolases, Brain, Child, Preschool, Clinical Protocols, Clinical Trials as Topic, Female, Follow-Up Studies, Genetic Vectors, Humans, Infant, Injections, Intraventricular, Magnetic Resonance Imaging, Male, Magnetic Resonance Spectroscopy, Genetic Therapy, Cohort Studies, Canavan Disease, Gene Transfer Techniques, Patient Selection
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gene Therapy of Canavan Disease: AAV-2 Vector for Neurosurgical Delivery of Aspartoacylase Gene ( ASPA ) to the Human Brain. https://app.cochat.ai/papers/10.1089/104303402760128612
- The paper
- Janson, C., McPhee, S., Bilaniuk, L., Haselgrove, J., Testaiuti, M., Freese, A., Wang, D.-J., Shera, D., Hurh, P., Rupin, J., Saslow, E., Goldfarb, O., Goldberg, M., Larijani, G., Sharrar, W., Liouterman, L., Camp, A., Kolodny, E., Samulski, J., & Leone, P. (2002). Gene Therapy of Canavan Disease: AAV-2 Vector for Neurosurgical Delivery of Aspartoacylase Gene ( ASPA ) to the Human Brain. Human Gene Therapy. https://doi.org/10.1089/104303402760128612
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.